ADVANCED PROGRAMME

ESMO 2014

Madrid, Spain

26-30 SEPTEMBER 2014

IMPORTANT DEADLINES

07 May 2014  Abstract submission and travel grant applications
18 June 2014  Early registration
23 July 2014  Group registration, participant names to be given
20 August 2014  Late-breaking abstract submission
20 August 2014  Late registration
### BASIC SCIENCE AND TRANSLATIONAL RESEARCH

**Saturday, 27 September 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30/11:30</td>
<td><strong>PATIENT CASES</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Cancer evolution: What can we learn from N=1 molecular studies?</strong></td>
</tr>
<tr>
<td></td>
<td><em>Co-Chairs: Michael Taylor, Toronto, ON, Canada and Tariq Enver, London, UK</em></td>
</tr>
<tr>
<td></td>
<td><strong>Evolution of acute lymphoblastic leukemia (ALL) in identical twins</strong></td>
</tr>
<tr>
<td></td>
<td><em>Tariq Enver, London, UK</em></td>
</tr>
<tr>
<td></td>
<td><strong>Clonal evolution of childhood cancers</strong></td>
</tr>
<tr>
<td></td>
<td><em>Michael Taylor, Toronto, ON, Canada</em></td>
</tr>
<tr>
<td></td>
<td><strong>Discussion</strong></td>
</tr>
</tbody>
</table>

**Sunday, 28 September 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15/10:45</td>
<td><strong>JOINT SYMPOSIUM: ESMO - JSMO</strong></td>
</tr>
<tr>
<td></td>
<td><strong>How to implicate genome sequencing data in oncology</strong></td>
</tr>
<tr>
<td></td>
<td><em>Co-Chairs: Jean-Yves Douillard, St. Herblain, France and Atsushi Ohtsu, Kashiwa, Japan</em></td>
</tr>
<tr>
<td></td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td></td>
<td><em>Jean-Yves Douillard, St. Herblain, France</em></td>
</tr>
<tr>
<td></td>
<td><strong>Potentially druggable gene alterations in gastrointestinal cancer</strong></td>
</tr>
<tr>
<td></td>
<td><em>Tatsuhiro Shibata, Tokyo, Japan</em></td>
</tr>
<tr>
<td></td>
<td><strong>A new molecular taxonomy for colorectal cancer – What are the</strong></td>
</tr>
<tr>
<td></td>
<td><strong>therapeutic implications?</strong></td>
</tr>
<tr>
<td></td>
<td><em>To be announced</em></td>
</tr>
<tr>
<td></td>
<td><strong>New insight of sequencing data in lung cancer</strong></td>
</tr>
<tr>
<td></td>
<td><em>Kazuto Nishio, Osaka, Japan</em></td>
</tr>
<tr>
<td></td>
<td><strong>Overcoming implementation challenges of personalised cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>therapy in patients with breast cancer</strong></td>
</tr>
<tr>
<td></td>
<td><em>Fabrice André, Villejuif, France</em></td>
</tr>
<tr>
<td></td>
<td><strong>Conclusions</strong></td>
</tr>
<tr>
<td></td>
<td><em>Atsushi Ohtsu, Kashiwa, Japan</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00/13:45</td>
<td><strong>KEYNOTE LECTURE</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Reclassifying cancer through genomics</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chair: Jos Jonkers, Amsterdam, Netherlands</em></td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Michael Stratton, London, UK</em></td>
</tr>
</tbody>
</table>

**Monday, 29 September 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00/12:30</td>
<td><strong>SPECIAL SYMPOSIUM</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Genomic instability from bench to bedside</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chair: Sheila Singh, Hamilton, ON, Canada</em></td>
</tr>
<tr>
<td></td>
<td><em>Co-Chair: Charles Swanton, London, UK</em></td>
</tr>
<tr>
<td></td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td></td>
<td><em>Charles Swanton, London, UK</em></td>
</tr>
<tr>
<td></td>
<td><strong>The emerging role of HELQ in homologous recombination repair</strong></td>
</tr>
<tr>
<td></td>
<td><strong>in ovarian cancer</strong></td>
</tr>
<tr>
<td></td>
<td><em>Rebecca Burrell, London, UK</em></td>
</tr>
<tr>
<td></td>
<td><strong>Replication stress and DNA damage response in solid tumours</strong></td>
</tr>
<tr>
<td></td>
<td><em>Jiri Bartek, Copenhagen, Denmark</em></td>
</tr>
<tr>
<td></td>
<td><strong>The interface between cancer numerical and structural</strong></td>
</tr>
<tr>
<td></td>
<td><strong>chromosomal instability: Mechanisms accelerating cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>diversity</strong></td>
</tr>
<tr>
<td></td>
<td><em>René Medema, Amsterdam, Netherlands</em></td>
</tr>
<tr>
<td></td>
<td><strong>Targeting cancer aneuploidy: Light at the end of the tunnel?</strong></td>
</tr>
<tr>
<td></td>
<td><em>Tak Mak, Toronto, ON, Canada</em></td>
</tr>
<tr>
<td></td>
<td><strong>Conclusions and clinical perspectives</strong></td>
</tr>
<tr>
<td></td>
<td><em>Sheila Singh, Hamilton, ON, Canada</em></td>
</tr>
</tbody>
</table>

**SCIENTIFIC COMMITTEE**

- **Charles Swanton, London, UK, Chair**
- **Jiri Bartek, Copenhagen, Denmark**
- **René Bernards, Amsterdam, Netherlands**
- **Rebecca Burrell, London, UK**
- **Carlos Caldas, Cambridge, UK**
- **Robert Gatenby, Tampa, FL, US**
- **Ramaswamy Govindan, St. Louis, MO, US**
- **Jos Jonkers, Amsterdam, Netherlands**
- **Tak Mak, Toronto, ON, Canada**
- **Carlo Maley, San Francisco, CA, USA**
- **Sheila Singh, Hamilton, ON, Canada**
- **Yosef Yarden, Rehovot, Israel**

Session timings may be subject to change within the same day.
Saturday, 27 September 2014

09:00/10:30 EDUCATIONAL SESSION
Update in the management of metastatic breast cancers
Chair: Angelo Di Leo, Prato, Italy
Co-Chair: Hernan Cortes-Funes, Madrid, Spain
Integration of molecular analyses in the management of metastatic breast cancer
Nicholas Tumer, London UK
Hormonal therapy
Ian Smith, London, UK
Optimal therapy for R2 positive
Angelo Di Leo, Prato, Italy

11:00/12:30 EDUCATIONAL SESSION
Management of breast cancer in specific populations
Chair: Fatima Cardoso, Lisbon, Portugal
Co-Chair: to be announced
Management of breast cancer in elderly patients
Elisheva Brain, Saint Cloud, France
Management of breast cancer in very young and pregnant women
Sybille Loibl, Neu-Isenburg, Germany
Management of breast cancer in males
Fatima Cardoso, Lisbon, Portugal

16:00/17:30 EDUCATIONAL SESSION (REPETITION)
Management of breast cancer in specific populations
Chair: Fatima Cardoso, Lisbon, Portugal
Co-Chair: to be announced
Management of breast cancer in elderly patients
Elisheva Brain, Saint Cloud, France
Management of breast cancer in very young and pregnant women
Sybille Loibl, Neu-Isenburg, Germany
Management of breast cancer in males
Fatima Cardoso, Lisbon, Portugal

Sunday, 28 September 2014

08:00/09:00 PATIENT CASES
Targeting intrinsic subtypes of metastatic breast cancer: The spectrum of sensitivity to endocrine therapy
Co-Chairs: Philippe Bedard, Toronto, ON, Canada and Javier Cortes, Barcelona, Spain
Dealing with resistance in ER positive disease
Philippe Bedard, Toronto, ON, Canada
Dealing with heterogeneity of triple negative breast cancer: From luminal androgen receptor to mesenchimal stem like subtype
Javier Cortes, Barcelona, Spain
Discussion

09:15/10:45 SPECIAL SYMPOSIUM
Residual disease after neoadjuvant therapies
Chair: Evandro de Azambuja, Brussels, Belgium
Co-Chair: Suzette Delaloge, Villejuif, France
Introduction
Suzette Delaloge, Villejuif, France
Quantifying post-neoadjuvant therapy residual disease and its impact on relapse risk
Faser Symmans, Houston, TX, US
Biological profiling of residual disease
Frederique Penault-Llorca, Clermont-Ferrand, France
Molecular imaging: Are we able to predict for residual disease?
Andreas Makris, Northwood, UK
How to design clinical trials in a post neo-adjuvant setting?
Andrew Tutt, London, UK
Conclusions and clinical perspectives
Evandro de Azambuja, Brussels, Belgium

14:15/15:45 EDUCATIONAL SESSION (REPETITION)
Update in the management of metastatic breast cancers
Chair: Angelo Di Leo, Prato, Italy
Co-Chair: Hernan Cortes-Funes, Madrid, Spain
Integration of molecular analyses in the management of metastatic breast cancer
Nicholas Tumer, London UK
Hormonal therapy
Ian Smith, London, UK
Optimal therapy for R2 positive
Angelo Di Leo, Prato, Italy

SCIENTIFIC COMMITTEE (EARLY STAGE)
Evandro De Azambuja, Brussels, Belgium, Chair
Hatem Azim, Brussels, Belgium
Agusí Barnadas, Barcelona, Spain
Fatima Cardoso, Lisbon, Portugal
Boon Chua, Melbourne, Australia
Angelo Di Leo, Prato, Italy
Peter Dubsky, Vienna, Austria
Sabine C. Linn, Amsterdam, Netherlands
Carlo Palmieri, Liverpool, UK
Alastair Thompson, Dundee, UK
Andrew Tutt, London, UK
Giuseppe Viale, Milan, Italy
**Monday, 29 September 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00/</td>
<td>CHALLENGE YOUR EXPERT (CYE)</td>
<td>Adjuvant treatment of breast cancer</td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td>Speaker: Martine Piccart, Brussels, Belgium</td>
</tr>
<tr>
<td>09:15/</td>
<td>SPECIAL SYMPOSIUM</td>
<td>Cancer immunotherapy in breast cancer: Dream or reality?</td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td>Chair: Giuseppe Curigliano, Milan, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-Chair: Sherene Loi, Melbourne, Australia</td>
</tr>
<tr>
<td>09:15/</td>
<td></td>
<td>Introduction</td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td>Giuseppe Curigliano, Milan, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Modulation of immune response in breast cancer and clinical implications of tumour dormancy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sherene Loi, Melbourne, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diagnostic and therapeutic implications of tumour-infiltrating lymphocytes in breast cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carsten Denkert, Berlin, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Contribution of immune response to anti-tumour effect of chemotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carmen Criscitiello, Naples, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Design of the ideal trial with immunotherapeutics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Giuseppe Curigliano, Milan, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Conclusions and clinical perspectives</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sherene Loi, Melbourne, Australia</td>
</tr>
<tr>
<td>14:15/</td>
<td>JOINT SYMPOSIUM: ESMO - ESTRO - ESSO</td>
<td>Integration of local therapy with systemic treatment in oligometastatic breast cancer</td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td>Co-Chairs: Christoph Zielinski, Vienna, Austria; Philip Poortmans, Tilburg, Netherlands; and Riccardo A. Audisio, St. Helens, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Introduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Christoph Zielinski, Vienna, Austria</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Combining systemic treatment with radiation therapy:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quantifying the therapeutic gain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Per Karlsson, Gothenburg, Sweden</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Design of clinical trials integrating local treatments with systemic therapy for M1 disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To be announced</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The role of surgery for M1 breast cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marjut Leidenius, Helsinki, Finland</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The role of radiation therapy for M1 breast cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Philip Poortmans, Tilburg, Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Conclusions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Riccardo A. Audisio, St. Helens, UK</td>
</tr>
<tr>
<td>16:00/</td>
<td>PATIENT CASES</td>
<td>Challenges in managing breast cancer in young patients</td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td>Co-Chairs: Hatem A. Azim, Brussels, Belgium; Marco Colleoni, Milan, Italy; and Sabine Linn, Amsterdam, Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genetic testing: When and for whom?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sabine Linn, Amsterdam, Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fertility counselling: What are the options?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hatem A. Azim, Brussels, Belgium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Optimal adjuvant hormonal therapy in premenopausal women</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marco Colleoni, Milan, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussion</td>
</tr>
</tbody>
</table>

**Tuesday, 30 September 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00/</td>
<td>CYE (REPEITION)</td>
<td>Adjuvant treatment of breast cancer</td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td>Speaker: Martine Piccart, Brussels, Belgium</td>
</tr>
</tbody>
</table>

**Scientific Committee (Metastatic)**

Giuseppe Curigliano, Milan, Italy, Chair

- Philippe Bedard, Toronto, ON, Canada
- Javier Cortés, Barcelona, Spain
- Carmen Criscitiello, Milan, Italy
- Carsten Denkert, Berlin, Germany
- Luca Giannì, Milan, Italy
- Roger Gomis, Barcelona, Spain
- Per Karlsson, Gothenburg, Sweden
- Antonio Lisemberg, Valencia, Spain
- Sherene Loi, Melbourne, Australia
- Sibylle Loibl, Neu-Isenburg, Germany
- Nicholas Turner, London, UK

Session timings may be subject to change within the same day.
Sunday, 28 September 2014

09:15/10:45  EDUCATIONAL SESSION
Actual issues in neurooncology
Chair: Roger Stupp, Zurich, Switzerland
Co-Chair: Mario Campone, St. Herblain, France
Brain metastases: To treat or not to treat?
Roger Stupp, Zurich, Switzerland
Molecular marker-based clinical decision-making today
Michael Weller, Zurich, Switzerland
Approaches to recurrent glioblastoma
Alba Brandes, Bologna, Italy

11:45/12:45  PATIENT CASES
Response, neurological function and other objectives in the management of patients with brain metastases
Co-Chairs: Martin Bendszus, Heidelberg, Germany; Anthony Chalmers, Glasgow, UK, and Enrico Franceschi, Bologna, Italy
What type of radiotherapy is indicated in brain metastases?
Anthony Chalmers, Glasgow, UK
Systemic therapy instead or in addition to irradiation?
Enrico Franceschi, Bologna, Italy
Challenges and pitfalls in radiological response assessment of brain metastases
Martin Bendszus, Heidelberg, Germany
Discussion

14:15/15:45  SPECIAL SYMPOSIUM
Current concepts and future avenues in meningioma
Chair: Jörg-Christian Tonn, Munich, Germany
Co-Chair: Matthias Preusser, Vienna, Austria
Introduction
Jörg-Christian Tonn, Munich, Germany
Meningioma: What can we learn from the biology for precision medicine?
Michel Kalamarides, Paris, France
Classification and molecular pathology of meningiomas
Christian Mawrin, Magdeburg, Germany
Radiotherapy of meningiomas
Damien Weber, Geneva, Switzerland
Molecular targeted, systemic therapies for meningiomas
Matthias Preusser, Vienna, Austria
Conclusions and clinical perspectives
Matthias Preusser, Vienna, Austria

SCIENTIFIC COMMITTEE
Roger Stupp, Zurich, Switzerland, Chair
Carmen Balana, Barcelona, Spain
Elizabeth Cohen-Jonathan-Moyal, Toulouse, France
Enrico Franceschi, Bologna, Italy
Evantha Galanis, Rochester, MN, USA
Kh Hoang-Xuan, Paris, France
Stefan Pfister, Heidelberg, Germany
Matthias Preusser, Vienna, Austria
Guido Reifenberger, Düsseldorf, Germany
Jean Seoane, Barcelona, Spain
Martin van den Bent, Rotterdam, Netherlands
Colin Watts, Cambridge, UK
Saturday, 27 September 2014

09:15/10:45 JOINT SYMPOSIUM: ESMO - CSCO
Global collaboration in phase I cancer drug development
Co-Chairs: Yi-Long Wu, Guangzhou, China and to be announced
Introduction
Yi Long Wu, Guangzhou, China
Phase I cancer drug development in China
Jin Li, Shanghai, China
Phase I cancer drug development in Europe
To be announced
How can pharmaceutical companies facilitate this global effort?
To be announced
Lung Cancer Asia Study Group: East
Yi-Long Wu, Guangzhou, China
Conclusions
To be announced

Sunday, 28 September 2014

09:00/10:30 SPECIAL SYMPOSIUM
Molecular profiling: Challenges and perspectives
Chair: Christian Dittrich, Vienna, Austria
Co-Chair: Jean-Charles Soria, Villejuif, France
Introduction
Jean-Charles Soria, Villejuif, France
How to design the trials to meet the perspectives of personalised cancer medicine
Sumithra Mandrekar, Rochester, NY, US
Platforms for tumour sequencing: Pertinence and practicability
Martijn Lolkema, Utrecht, Netherlands
Overview of trials testing tumour molecular profiling
Jean-Charles Soria, Villejuif, France
Targets, targets everywhere but not a drug to give
Udai Banerji, London, UK
Conclusions and clinical perspectives
Christian Dittrich, Vienna, Austria

Monday, 29 September 2014

10:30/11:30 PATIENT CASES
Demonstrating the emergence of resistance
Co-Chairs: Elisabeth de Vries, Groningen, Netherlands, and Ruth Plummer, Newcastle upon Tyne, UK
How to overcome drug resistance
Ruth Plummer, Newcastle upon Tyne, UK
Molecular imaging to demonstrate changes in tumour characteristics over the time
Elisabeth de Vries, Groningen, Netherlands
Discussion

13:00/13:50 KEYNOTE LECTURE
Rational drug combinations
Chair: Timothy Yap, Sutton, UK
Concepts and pre-clinical proof of principle
René Bernards, Amsterdam, Netherlands
Clinical results and future perspectives
Jan Schellens, Amsterdam, Netherlands

SCIENTIFIC COMMITTEE
Christian Dittrich, Vienna, Austria, Chair
Ahmad Awada, Brussels, Belgium
Udai Banerji, Sutton, UK
Elisabeth de Vries, Groningen, Netherlands
Elizabeth A. Eisenhauer, Kingston, ON, Canada
Manuel Hidalgo, Madrid, Spain
Annette K. Larsen, Paris, France
Ruth Plummer, Newcastle upon Tyne, UK
Roberto Salgado, Brussels, Belgium
Patrick Schöffski, Leuven, Belgium
Giampaolo Tortora, Verona, Italy
Christopher Twelves, Leeds, UK
FAMILIAL CANCERS AND GENETIC SYNDROMES

Saturday, 27 September 2014

09:15/10:45 SPECIAL SYMPOSIUM
Germline genetics: Important issues for oncologists
Chair: Dominique Stoppa-Lyonnet, Paris, France
Co-Chair: Rosalind Eeles, Sutton, UK
Introduction
Dominique Stoppa-Lyonnet, Paris, France
Current application of genetic variants to clinical management
Gareth Evans, Sutton, UK
Considerations for the oncologist when referring for testing:
Which tests are available and why?
Thierry Frebourg, Rouen, France
Genetic risk and its implications for cancer surveillance
Rosalind Eeles, Sutton, UK
Considerations for the oncologist when treating cancer patients
with germline mutations
Gillian Mitchell, Melbourne, Australia
Conclusions and clinical perspectives
Rosalind Eeles, Sutton, UK

Sunday, 28 September 2014

09:15/10:15 PATIENT CASES
Clinical and ethical issues in cancer genetics
Co-Chairs: Anneke Lucassen, Southampton, UK and Fred Menko, Amsterdam, Netherlands
Early onset renal cancer
Fred Menko, Amsterdam, Netherlands
Ethical issues surrounding genetic results
Anneke Lucassen, Southampton, UK
Discussion

SCIENTIFIC COMMITTEE
Rosalind Eeles, Sutton, UK, Chair
Judith Balmaña, Barcelona, Spain
Elena Castro, Sutton, UK
Gareth Evans, Manchester, UK
Kari Hemminki, Heidelberg, Germany
Shirley Hodgson, London, UK
Fred Menko, Amsterdam, Netherlands
Gillian Mitchell, Melbourne, Australia
Kenneth Muir, Coventry, UK
Dominique Stoppa-Lyonnet, Paris, France
Hans Vasen, Leiden, Netherlands
BOOKING YOUR OWN CONFERENCE TRAVEL IS EASY AS ABC

WITH THE GLOBAL ONLINE BOOKING TOOL FROM STAR ALLIANCE CONVENTIONS PLUS

No matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to ESMO 2014 in Madrid.

And with over 21,900 flights a day to 1,329 destinations across 195 countries, our 28 member airlines extend the same choice to any future conferences you are planning to attend.

You can also save money when you book your flights. Simply quote the Convention Code SK07A03 and you plus one travelling companion will receive a special discount. Better still, no matter which Star Alliance member airline’s frequent flyer programme you belong to, you can earn and redeem miles across all 28 airlines.

For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to www.staralliance.com/conventionsplus
Saturday, 27 September 2014

11:00/12:30 EDUCATIONAL SESSION
Clinical impact of tumour biology in the management of oesophago-gastric cancer
Chair: Florian Lordick, Leipzig, Germany
Co-Chair: Fernando Rivera Herrero, Madrid, Spain
Should locally advanced adenocarcinoma of the oesophagus and of the gastroesophageal junction (GEJ) be managed in the same way?
Michael Stahl, Essen, Germany
Surgery: Does response to preoperative therapy modify the extension of surgical resection? When is salvage surgery indicated?
Arnulf Hölscher, Cologne, Germany
Novel targets in the treatment of advanced gastric cancer: What exists already and what comes next?
Florian Lordick, Leipzig, Germany

14:15/15:45 EDUCATIONAL SESSION
Optimising the treatment of colorectal cancer
Chair: Richard Adams, Cardiff, UK
Co-Chair: to be announced
Are there any useful tools when deciding about adjuvant chemotherapy?
Richard Adams, Cardiff, UK
How to select first line chemotherapy in metastatic colorectal cancer
Claus Henning Koehne, Oldenburg, Germany
Optimising biomarkers based management beyond KRAS
Sabine Tejpar, Leuven, Belgium

16:00/17:30 EDUCATIONAL SESSION
A multidisciplinary approach to locoregionally advanced rectal cancer
Chair: Robert Glynne-Jones, Northwood, UK
Co-Chair: Eduardo Diaz Rubio, Madrid, Spain
Radiotherapy: Which type and for whom?
Robert Glynne-Jones, Northwood, UK
Neoadjuvant and adjuvant chemotherapy: Is there a standard of care or not yet?
Andrés Cervantes, Valencia, Spain
Is there still room for improvement in surgery for locoregionally advanced rectal cancer?
Cornelis van de Velde, Leiden, Netherlands

Sunday, 28 September 2014

08:00/09:00 PATIENT CASES
Challenges in oligometastatic disease: Ways towards long-term survival of metastatic colorectal cancer
Co-Chairs: Theo Ruers, Amsterdam, Netherlands and Alberto Sobrero, Genoa, Italy
Irresectable liver metastases: What do local ablative treatments contribute?
Theo Ruers, Amsterdam, Netherlands
What drives long-term survival with systemic treatment?
Alberto Sobrero, Genoa, Italy
Discussion

11:00/12:30 EDUCATIONAL SESSION (REPETITION)
A multidisciplinary approach to locoregionally advanced rectal cancer
Chair: Robert Glynne-Jones, Northwood, UK
Co-Chair: Eduardo Eduardo Diaz Rubio, Madrid, Spain
Radiotherapy: Which type and for whom?
Robert Glynne-Jones, Northwood, UK
Neoadjuvant and adjuvant chemotherapy: Is there a standard of care or not yet?
Andrés Cervantes, Valencia, Spain
Is there still room for improvement in surgery for locoregionally advanced rectal cancer?
Cornelis van de Velde, Leiden, Netherlands

14:15/15:45 SPECIAL SYMPOSIUM
Advances in precision medicine of metastatic colorectal cancer
Chair: Will Steward, Leicester, UK
Co-Chair: Thomas Seufferlein, Ulm, Germany
Introduction
Thomas Seufferlein, Ulm, Germany
New molecular classification of colorectal cancer
Kristian Homsics, Lausanne, Switzerland
Emerging druggable targets in colorectal cancer
Federica Di Nicolantonio, Candiolo, Italy
Signal transduction inhibitors and pipeline drugs
Josep Tabernero, Barcelona, Italy
Immunotherapy and vaccines
Pierpaolo Correale, Siena, Italy
Liquid biopsies and “on treatment” markers
Gerald Prager, Vienna, Austria
Conclusions and clinical perspectives
Will Steward, Leicester, UK

SCIENTIFIC COMMITTEE (COLORECTAL)
Dirk Arnold, Freiburg, Germany, Chair
Eduardo Diaz-Rubio, Madrid, Spain
Federica Di Nicolantonio, Candiolo, Italy
Axel Grothey, Rochester, MN, USA
Thomas Grünberger, Vienna, Austria
Corrie Marijnen, Leiden, Netherlands
Per Pfeiffer, Odense, Denmark
Gerald Prager, Vienna, Austria
Thomas Seufferlein, Ulm, Germany
Matthew Seymour, Leeds, UK
Alberto Sobrero, Genoa, Italy
Sabine Teijpar, Leuven, Belgium
Christophe Tournigand, Créteil, France
Monday, 29 September 2014

10:30/11:30 MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)
Locally advanced pancreatic cancer
Chair: Eric Van Cutsem, Leuven, Belgium
Co-Chair: Bengt Glimelius, Uppsala, Sweden
Radiation oncology
Bengt Glimelius, Uppsala, Sweden
Medical oncology
Eric Van Cutsem, Leuven, Belgium
Discussion

11:45/12:45 MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)
Sequence of treatment in colorectal cancer with synchronous metastases
Chair: Bernard Nordlinger, Boulogne, France
Co-Chair: Gunnar Folprecht, Dresden, Germany
Surgery
Bernard Nordlinger, Boulogne, France
Medical oncology
Gunnar Folprecht, Dresden, Germany
Discussion

11:45/12:45 PATIENT CASES
Integrating systemic and locoregional therapies in a patient with advanced hepatocellular carcinoma (HCC)
Co-Chairs: Riccardo Lencioni, Pisa, Italy and Chris Verlype, Leuven, Belgium
Systemic therapy
Chris Verlype, Leuven, Belgium
Locoregional therapy
Riccardo Lencioni, Pisa, Italy
Discussion

14:15/15:15 MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)
Multidisciplinary management of peritoneal carcinomatosis
Chair: Dominique Elias, Villejuif, France
Co-Chair: Cornelis Punt, Amsterdam, Netherlands
Surgery
Dominique Elias, Villejuif, France
Medical oncology
Cornelis Punt, Amsterdam, Netherlands
Discussion

14:15/15:45 EDUCATIONAL SESSION (REPETITION)
Optimising the treatment of colorectal cancer
Chair: Richard Adams, Cardiff, UK
Co-Chair: to be announced
Are there any useful tools when deciding about adjuvant chemotherapy?
Richard Adams, Cardiff, UK
How to select first line chemotherapy in metastatic colorectal cancer
Claus-Henning Koehne, Oldenburg, Germany
Optimising biomarkers based management beyond KRAS
Sabine Tejpar, Leuven, Belgium

16:00/17:30 SPECIAL SYMPOSIUM
Towards personalised medicine in gastric, pancreatic and liver cancer: From “omics” research to treatment
Chair: Erika Martinelli, Naples, Italy
Co-Chair: Michel Ducrée, Villejuif, France
Introduction
Michel Ducrée, Villejuif, France
What are the new tools available?
Peter Schirmacher, Heidelberg, Germany
Hepatocellular carcinoma (HCC)
Augusto Villanueva, London, UK
Pancreatic cancer
Manuel Hidalgo, Madrid, Spain
Gastric cancer
Patrick Tan, Singapore
Conclusions and clinical perspectives
Erika Martinelli, Naples, Italy

SCIENTIFIC COMMITTEE (NON-COLORECTAL)
Andrés Cervantes, Valencia, Spain, Chair
Regina Beets-Tan, Maastricht, Netherlands
Fátima Carneiro, Porto, Portugal
Thierry Conroy, Vandœuvre-lès-Nancy, France
Michel Ducrée, Villejuif, France
Karim Haustermans, Leuven, Belgium
Florian Lordick, Lübeck, Germany
Teresa Macarulla, Barcelona, Spain
Erika Martinelli, Naples, Italy
Fernando Rivera, Santander, Spain
Juan Valle, Manchester, UK
Chris Verlype, Leuven, Belgium

Session timings may be subject to change within the same day
Saturday, 27 September 2014

08:00/09:00 - CHALLENGE YOUR EXPERT (CYE)
Management of relapsed germ cell tumours
Speaker: Joerg Beyer, Zurich, Switzerland

08:00/09:00 - PATIENT CASES
Multimodal treatment approaches in bladder cancer
Co-Chairs: Thierry Lebret, Suresnes, France; Nicholas James, Birmingham, UK and David Solit, New York, NY, US
The role of surgery in advanced bladder cancer
Thierry Lebret, Suresnes, France
Precision drug treatment for bladder cancer
David Solit, New York, NY, US
Is surgery always necessary?
Nicholas James, Birmingham, UK
Discussion

14:00/15:45 - SPECIAL SYMPOSIUM
Precision medicine in prostate cancer
Chair: Eleni Efstathiou, Athens, Greece
Co-Chair: Eleni Efstathiou, Athens, Greece
Introduction
Eleni Efstathiou, Athens, Greece
Prostate carcinogenesis: What have we learnt from next generation sequencing?
Levi A. Garraway, Boston, MA, US
Do we need a new taxonomy for prostate cancer?
Mark Rubin, New York, NY, US
Will circulating biomarkers help to deliver precision medicine?
David Olmos, Madrid, Spain
Immunotherapy for prostate cancer?
Charles Drake, Baltimore, MD, US
Where next for precision medicine for prostate cancer?
Eleni Efstathiou, Athens, Greece
Conclusions and clinical perspectives
Mark Rubin, New York, NY, US

Sunday, 28 September 2014

08:00/09:00 - CYE (REPEITION)
Management of relapsed germ cell tumours
Speaker: Joerg Beyer, Zurich, Switzerland

11:00/12:30 - EDUCATIONAL SESSION (REPEITION)
Update in genitourinary oncology
Chair: Bernard Escudier, Villejuif, France
Co-Chair: Ian Tannock, Toronto, ON, Canada
Optimal sequence of treatment for metastatic prostate cancer
Cora Sternberg, Rome, Italy
How to deal with unresectable and inoperable bladder cancer
Maria de Santis, Vienna, Austria
Treatment of metastatic renal cell carcinoma (RCC): Present and future
Bernard Escudier, Villejuif, France

Monday, 29 September 2014

08:00/09:00 - PATIENT CASES
Treatment of castration-resistant prostate cancer (CRPC) in special situations
Co-Chairs: Gerhardt Attard, Surrey, UK, Anna Falanga, Bergamo, Italy and Stephane Oudard, Paris, France
Treating elderly patients
Stephane Oudard, Paris, France
When is prostate cancer truly androgen independent?
Gerhardt Attard, Surrey, UK
Bone marrow carcinosis and disseminated intravascular coagulation (DIC)
Anna Falanga, Bergamo, Italy
Discussion

09:15/10:45 - SPECIAL SYMPOSIUM
Beyond tumour heterogeneity: New pathways in kidney cancer
Chair: Viktor Grünwald, Hannover, Germany
Co-Chair: Cora Sternberg, Rome, Italy
Introduction
Cora Sternberg, Rome, Italy
Molecular classification of kidney cancer
Andrew Futreal, Houston, TX, US
Precision medicine in kidney cancer and clinical trial designs
James Larkin, London, UK
Immunotherapy: Myth or reality?
David McDermott, Boston, MA, US
New drugs and new targets (phase I)
Emiliano Calvo, Madrid, Spain
Conclusions and clinical perspectives
Viktor Grünwald, Hannover, Germany
SCIENTIFIC COMMITTEE (PROSTATE)
Eleni Efstathiou, Athens, Greece, Chair
Gerhardt Attard, Sutton, UK
Karim Fizazi, Villejuif, France
Silke Gillessen, St. Gallen, Switzerland
Axel Heidenreich, Aachen, Germany
David Olmos, Madrid, Spain
Stephane Oudard, Paris, France
Chris Parker, Sutton, UK
Mark Rubin, New York, NY, US
Jack Schalken, Nijmegen, Netherlands
Avishay Sella, Zerifin, Israel
Anders Widmark, Umeå, Sweden

SCIENTIFIC COMMITTEE (NON-PROSTATE)
James Larkin, London, UK, Chair
Michael Alchison, Glasgow, UK
Axel Bex, Amsterdam, Netherlands
Emiliano Calvo, Madrid, Spain
Maria De Santis, Vienna, Austria
Bernard Escudier, Villejuif, France
Viktor Grünwald, Hannover, Germany
Nicholas James, Birmingham, UK
Arnaud Mejean, Paris, France
Gerald Mickisch, Bremen, Germany
Manuela Schmidinger, Vienna, Austria
Cora Sternberg, Rome, Italy
Saturday, 27 September 2014

08:00/09:00  CHALLENGE YOUR EXPERT (CYE)
Medical treatment for advanced endometrial cancer
Speaker: Cristiana Sessa, Bellinzona, Switzerland

14:15/15:45  EDUCATIONAL SESSION
Ovarian cancer
Chair: Antonio Gonzalez Martin, Madrid, Spain
Co-Chair: Nicoletta Colombo, Milan, Italy
Antiangiogenic therapy: Where in the disease pathway and which patients?
Antonio Gonzalez Martin, Madrid, Spain
How to recognise and treat low grade tumours
Jonathan Ledermann, London, UK
Treatment for relapsing patients
Sandro Pignata, Naples, Italy

Sunday, 28 September 2014

08:00/09:00  CYE (REPETITION)
Medical treatment for advanced endometrial cancer
Speaker: Cristiana Sessa, Bellinzona, Switzerland

09:30/10:30  MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)
Management of localised endometrial cancer
Chair: Carien L. Creutzberg, Leiden, Netherlands
Co-Chair: Mansoor Mirza, Copenhagen, Denmark
Radiotherapy
Carien L. Creutzberg, Leiden, Netherlands
Clinical oncology
Mansoor Mirza, Copenhagen, Denmark
Discussion

11:00/12:30  SPECIAL SYMPOSIUM
Targeted therapy in gynaecological cancer
Chair: Andres Poveda, Valencia, Spain
Co-Chair: Eric Pujade-Lauraine, Paris, France
Introduction
Eric Pujade-Lauraine, Paris, France
Emerging molecular targets in gynaecological cancer
David Huntsman, Vancouver, BC, Canada
The impact of targeted therapy in cervical and endometrial cancer
Ana Oaknin, Barcelona, Spain
Targeted therapy of ovarian cancer: Beyond angiogenesis
Nicoletta Colombo, Milan, Italy
The coming decade
Michael Bookman, Tucson, AZ, US
Conclusions and clinical perspectives
Andres Poveda, Valencia, Spain

14:15/15:45  EDUCATIONAL SESSION (REPETITION)
Ovarian cancer
Chair: Antonio Gonzalez Martin, Madrid, Spain
Co-Chair: Nicoletta Colombo, Milan, Italy
Antiangiogenic therapy: Where in the disease pathway and which patients?
Antonio Gonzalez Martin, Madrid, Spain
How to recognise and treat low grade tumours
Jonathan Ledermann, London, UK
Treatment for relapsing patients
Sandro Pignata, Naples, Italy

Monday, 29 September 2014

08:00/09:00  PATIENT CASES
Primary surgery or neoadjuvant chemotherapy for ovarian cancer: How should we select the patients?
Co-Chairs: Charles Gourley, Edinburgh, UK; Christian Marth, Innsbruck, Austria and Isabelle Ray-Coquard, Lyon, France
The role of upfront surgery
Christian Marth, Innsbruck, Austria
Best neo-adjuvant therapy: Options for selected patients
Isabelle Ray-Coquard, Lyon, France
Is there a molecular analysis that can help us define a subgroup of patients?
Charles Gourley, Edinburgh, UK
Discussion

SCIENTIFIC COMMITTEE
Andres Poveda, Valencia, Spain, Chair
Michael Bookman, Tucson, AZ, US
Antonio González Martin, Madrid, Spain
Philipp Harter, Essen, Germany
Jonathan Ledermann, London, UK
Christian Marth, Innsbruck, Austria
Mansoor Mirza, Copenhagen, Denmark
José Palacios Calvo, Madrid, Spain
Timothy Perren, Leeds, UK
Sandro Pignata, Naples, Italy
Eric Pujade-Lauraine, Paris, France
Isabelle Ray-Coquard, Lyon, France

Session timings may be subject to change within the same day
Saturday, 27 September 2014

14:15/ 15:45 SPECIAL SYMPOSIUM
Targeting signalling pathways in haematological malignancies: Are we close to the end of histopathological classification and the chemotherapy era?
Chair: Andreas Rosenwald, Würzburg, Germany
Co-Chair: Faith Davies, Sutton, UK
Introduction: Is a purely biological classification of lymphoma possible?
Faith Davies, Sutton, UK
Targeting kinases and relevance in B-cell lymphomas (BCL)
Ingo Ringshausen, Munich, Germany
Targeting the BCL-2 pathway
Anthony Letai, Boston, MA, US
Targeting the cyclins
Paolo Ghia, Milan, Italy
Translating genetics into clinical care
Thorsten Zenz, Heidelberg, Germany
Conclusions: Is this the end of chemotherapy in lymphoma?
Andreas Rosenwald, Würzburg, Germany

Monday, 29 September 2014

09:15/ 10:15 PATIENT CASES
Imaging decisions in haematological malignancies
Co-Chairs: Josee Zijlstra, Amsterdam, Netherlands and Christina Messiou, Surrey, UK
Lymphoma: What to do and when?
Josee Zijlstra, Amsterdam, Netherlands
Myeloma: What to do and when?
Christina Messiou, Surrey, UK
Discussion

11:00/ 12:30 JOINT SYMPOSIUM: ESMO - EANM
Impact of molecular imaging on management of lymphoma
Co-Chairs: Michele Ghielmini, Bellinzona, Switzerland and Wim Oyen, Nijmegen, Netherlands
Introduction
Wim Oyen, Nijmegen, Netherlands
PET-based decisions in Hodgkin’s lymphoma
Martin Hutchings, Copenhagen, Denmark
PET-based decisions in non Hodgkin’s lymphoma
Josee Zijlstra, Amsterdam, Netherlands
Potential and pitfalls in PET-imaging of lymphoma
To be announced
PET-based response criteria in lymphoma: Current status and future directions
Michel Meignan, Créteil, France
Conclusions
Michele Ghielmini, Bellinzona, Switzerland

16:00/ 17:30 EDUCATIONAL SESSION
Major lymphoma subtypes in the elderly
Chair: Martin Dreyling, Munich, Germany
Co-Chair: Michele Ghielmini, Bellinzona, Switzerland
Diffuse large cell lymphoma: 8x R-CHOP 21: Is there one standard therapy for all patients?
Peter Johnson, Southampton, UK
Follicular lymphoma: Is it a boring disease?
Martin Dreyling, Munich, Germany
Chronic lymphocytic leukemia (CLL): Is treatment the same as in younger patients?
Michael Hallek, Cologne, Germany

SCIENTIFIC COMMITTEE
Faith Davies, Sutton, UK, Chair
Peter Campbell, Cambridge, UK
Enrico Derenzini, New York, NY, US
Paolo Ghia, Milan, Italy
Enrico Ocío, Salamanca, Spain
Gert Ossenkopppele, Amsterdam, Netherlands
Mariano Provenicio, Madrid, Spain
Ingo Ringshausen, Munich, Germany
Andreas Rosenwald, Wuerzburg, Germany
Evangelos Terpos, Athens, Greece
Elena Zamagni, Bologna, Italy
Thorsten Zenz, Heidelberg, Germany
HEAD AND NECK CANCER

Saturday, 27 September 2014

08:00/09:00 CHALLENGE YOUR EXPERT (CYE)
Larynx preservation: How should we decide the best treatment?
Speaker: Jean-Louis Lefebvre, Lille, France

11:00/12:30 SPECIAL SYMPOSIUM
Personalised medicine in head and neck cancer
Chair: Sandrine Faivre, Clichy, France
Co-Chair: Juan J. Grau, Barcelona, Spain
Introduction
Juan J. Grau, Barcelona, Spain
New targets in squamous cell carcinoma
Jean-Pascal Machiels, Brussels, Belgium
New targets in salivary gland cancer
Andrew Futreal, Houston, TX, US
Immunotherapy for head and neck cancer
Erik Hooijberg, Amsterdam, Netherlands
Next generation technology for next generation trials
Christophe Le Tourneau, Paris, France
Conclusion and clinical perspectives
Sandrine Faivre, Clichy, France

Sunday, 28 September 2014

08:00/09:00 CYE (REPEITION)
Larynx preservation: How should we decide the best treatment?
Speaker: Jean-Louis Lefebvre, Lille, France

11:00/12:00 MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)
Locally advanced nasopharyngeal carcinoma
Chair: Lisa Licitra, Milan, Italy
Co-Chair: Jean Bourhis, Lausanne, Switzerland
Medical oncology
Lisa Licitra, Milan, Italy
Radiotherapy
Jean Bourhis, Lausanne, Switzerland
Discussion

14:30/15:30 PATIENT CASES
Treatment of medullary thyroid cancer (MTC)
Co-Chairs: Jaume Capdevila, Barcelona, Spain and Sophie Leboulleux, Villejuif, France
Sub-classification and treatment of MTC
Sophie Leboulleux, Villejuif, France
Practical management of tyrosine-kinase inhibitor (TKI)
Jaume Capdevila, Barcelona, Spain
Discussion

SCIENTIFIC COMMITTEE
Sandrine Faivre, Clichy, France, Chair
Jean Bourhis, Lausanne, Switzerland
Andreas Dietz, Leipzig, Germany
Cai Grau, Aarhus, Denmark
Juan José Grau, Barcelona, Spain
Kevin Harrington, London, UK
Florence Huguet, Paris, France
Gabriela Kornek, Vienna, Austria
Christophe Le Tourneau, Paris, France
Lisa Licitra, Milan, Italy
Jean-Pascal Machiels, Brussels, Belgium
Amanda Psyrri, Athens, Greece
IMMUNOTHERAPY OF CANCER

Saturday, 27 September 2014

11:00/12:30  JOINT SYMPOSIUM: ESMO - ESP
Tissue markers for immuno-oncology
Co-Chairs: Fatima Carneiro, Porto, Portugal and Fortunato Ciardiello, Naples, Italy

Introduction
Fortunato Ciardiello, Naples, Italy
The importance of the preanalytical phase (the proper handling of specimens from site of biopsy to pathology lab, fixation etc) for immunohistochemistry
To be announced

How to quantify immunohistochemical slides
To be announced

Importance of external quality assessment in immuno-oncology
To be announced

What the oncologist needs from the pathologist
To be announced

Conclusions
Fatima Carneiro, Porto, Portugal

13:00/13:45  KEYNOTE LECTURE
Delivering precision immunotherapy
Chair: George Coukos, Lausanne, Switzerland
Speaker: Carl June, Philadelphia, PA, US

Sunday, 28 September 2014

14:15/15:45  SPECIAL SESSION
Evasion, activation and manipulation of the cancer immuno response
Chair: Sjoerd van der Burg, Leiden, Netherlands
Co-Chair: Inge Marie Svane, Herlev, Denmark

Introduction
Sjoerd van der Burg, Leiden, Netherlands

Overcoming immune evasion
Daniel Speiser, Lausanne, Switzerland

Precision medicine in immunotherapy
George Coukos, Lausanne, Switzerland

Building rational combinations in immunotherapy
Michele Maio, Siena, Italy

Clinical interpretation of response with immunotherapy
John Haanen, Amsterdam, Netherlands

Conclusions and clinical perspectives
Inge Marie Svane, Herlev, Denmark

16:00/17:30  EDUCATIONAL SESSION
Fundamental principles of cancer immunotherapy: What the clinician needs to know
Chair: Suzy Scholl, Paris, France
Co-Chair: Ulrich Keilholz, Berlin, Germany

Fundamental principles of antitumour immune response: A summary for the clinician
Suzy Scholl, Paris, France

Fundamental mechanisms of tumour immune evasion: A summary for the clinician
Sjoerd van der Burg, Leiden, Netherlands

How therapeutic immunomodulation can restore antitumour immunity: From theory to practice
Mario Sznol, New Haven, CT, US

Monday, 29 September 2014

09:00/10:30  SPECIAL SYMPOSIUM
Activating immune response to cancer
Chair: Michele Maio, Siena, Italy
Co-Chair: Suzy Scholl, Paris, France

Introduction
Suzy Scholl, Paris, France

Tumour infiltrating lymphocytes (TIL) and their use in therapy
Inge Marie Svane, Herlev, Denmark

Adaptive therapy with engineered T-cells
Carl June, Philadelphia, PA, US

New developments in clinical vaccinations
Ulrich Keilholz, Berlin, Germany

Rational combinations in cancer immunotherapy
Ignacio Melero, Pamplona, Spain

Conclusions and clinical perspectives
Michele Maio, Siena, Italy

14:30/15:30  PATIENT CASES
Immunotherapy in clinical practice
Chair: Antoni Ribas, Los Angeles, CA, US and Dirk Schadenberg, Essen, Germany

Challenges in the assessment of response to cancer immunotherapy
Antoni Ribas, Los Angeles, CA, US

Management of toxicity during immunotherapy
Dirk Schadenberg, Essen, Germany

Discussion

SCIENTIFIC COMMITTEE
George Coukos, Lausanne, Switzerland, Chair

Hinrich Abken, Cologne, Germany
Luis de la Cruz Merino, Seville, Spain
John Haanen, Amsterdam, Netherlands
Robert Hawkins, Manchester, UK
Ulrich Keilholz, Berlin, Germany

Michele Maio, Siena, Italy
Ignacio Melero, Pamplona, Spain
Suzy Scholl, Paris, France
Inge-Marie Svane, Copenhagen, Denmark
Sjoerd van der Burg, Leiden, Netherlands
### Saturday, 27 September 2014

**08:00/09:00** | **PATIENT CASES**  
**Therapeutic challenges in oncogene addicted lung cancers**  
Co-Chairs: Silvia Novello, Orbassano, Italy and Ken O’Byrne, Brisbane, Australia  
A case of EGFR mutation in squamous cell carcinoma  
Silvia Novello, Orbassano, Italy  
A ROS1 translocated NSCLC patient  
Ken O’Byrne, Brisbane, Australia  
Discussion

**09:15/10:45** | **EDUCATIONAL SESSION**  
**Systemic treatment of metastatic NSCLC**  
Chair: Benjamin Besse, Villejuif, France  
Co-Chair: Lucio Crinò, Perugia, Italy  
Non-oncogenic addicted NSCLC patients: What is the best approach?  
Benjamin Besse, Villejuif, France  
Oncogenesis addiction, biomarkers: Who should be tested and when?  
Pasi Jänne, Boston, MA, US  
How do we define progression and what is to be done?  
Anne-Marie Dingemans, Maastricht, Netherlands

**11:00/12:30** | **EDUCATIONAL SESSION**  
**Clinical issues in metastatic NSCLC**  
Chair: Tony S.K. Mok, Hong Kong, China  
Co-Chair: Jean-Yves Douillard, St. Herblain, France  
Is there anything new in squamous cells?  
Witold Eberhardt, Essen, Germany  
The best approach to oligometastatic NSCLC  
Jaroslaw Kuzdzal, Krakow, Poland  
Optimal sequence of administration for targeted agents and chemotherapy  
Tony S.K. Mok, Hong Kong, China

**14:30/15:30** | **PATIENT CASES**  
**Challenging cases of oligometastatic NSCLC**  
Co-Chairs: Umberto Ricardi, Turin, Italy and Michael Thomas, Ulm, Germany  
An EGFR mutated patient with a right/left -sided located T3N0 non-squamous cell lung cancer and a solitary right/left adrenal gland metastasis  
Michael Thomas, Ulm, Germany  
A patient with a right upper lobe peripherally located T1b adenocarcinoma with a bone metastasis in the left rib 9 and in dorsal vertebra 4  
Umberto Ricardi, Turin, Italy  
Discussion

---

### Sunday, 28 September 2014

**09:00/10:30** | **EDUCATIONAL SESSION (REpetition)**  
**Systemic treatment of metastatic NSCLC**  
Chair: Benjamin Besse, Villejuif, France  
Co-Chair: Lucio Crinò, Perugia, Italy  
Non-oncogenic addicted NSCLC patients: What is the best approach?  
Benjamin Besse, Villejuif, France  
Oncogenesis addiction, biomarkers: Who should be tested and when?  
Pasi Jänne, Boston, MA, US  
How do we define progression and what is to be done?  
Anne-Marie Dingemans, Maastricht, Netherlands

**11:00/12:30** | **EDUCATIONAL SESSION (REpetition)**  
**Clinical issues in metastatic NSCLC**  
Chair: Tony S.K. Mok, Hong Kong, China  
Co-Chair: Jean-Yves Douillard, St. Herblain, France  
Is there anything new in squamous cells?  
Witold Eberhardt, Essen, Germany  
The best approach to oligometastatic NSCLC  
Jaroslaw Kuzdzal, Krakow, Poland  
Optimal sequence of administration for targeted agents and chemotherapy  
Tony S.K. Mok, Hong Kong, China

**14:15/15:15** | **MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)**  
**Management of brain metastasis: Surgery vs radiation vs late intervention**  
Chair: Dirk De Ruyscher, Leuven, Belgium  
Co-Chair: Lucio Crinò, Perugia, Italy  
Medical oncology  
Lucio Crinò, Perugia, Italy  
Radiotherapy  
Dirk De Ruyscher, Leuven, Belgium  
Discussion
Monday, 29 September 2014

08:00/09:00 CHALLENGE YOUR EXPERT (CYE)
SCLC: Current approaches and the role of radiotherapy (thoracic and PCI) in stage IV disease
Speaker: Thierry Le Chevalier, Villejuif, France

09:00/10:30 SPECIAL SYMPOSIUM
The evolving role of systemic treatment in advanced NSCLC
Chair: Jean-Charles Soria, Villejuif, France
Co-Chair: Ken O’Byrne, Brisbane, Australia
Introduction
Ken O’Byrne, Brisbane, Australia
Reclassifying lung cancer and molecular diagnostic
Ramaswamy Govindan, St. Louis, MO, US
Targeting tumour addiction
Rafal Dziadziuszko, Gdansk, Poland
Secondary resistance to systemic treatment
Egbert Smit, Amsterdam, Netherlands
Immunotherapy: Current status
Martin Reck, Grosshansdorf, Germany
Conclusions and clinical perspectives
Jean-Charles Soria, Villejuif, France

Tuesday, 30 September 2014

08:00/09:00 CYE (REPEATITION)
SCLC: Current approaches and the role of radiotherapy (thoracic and PCI) in stage IV disease
Speaker: Thierry Le Chevalier, Villejuif, France

16:00/17:30 SPECIAL SYMPOSIUM
Diagnostic and therapeutic challenges in thoracic malignancies
Chair: Johan Vansteenkiste, Leuven, Belgium
Co-Chair: Suresh Senan, Amsterdam, Netherlands
Introduction
Suresh Senan, Amsterdam, Netherlands
Optimal assessment of an additional lung nodule in a patient with potential for cure
Christophe Dooms, Leuven, Belgium
What is the place of less invasive surgery in lung cancer?
Giulia Veronesi, Milan, Italy
Stereotactic ablative radiotherapy in early stage NSCLC
Suresh Senan, Amsterdam, Netherlands
Defining the role of targeted therapies in early stage NSCLC
Solange Peters, Lausanne, Switzerland
Conclusions and clinical perspectives
Johan Vansteenkiste, Leuven, Belgium
# MELANOMA AND OTHER SKIN TUMOURS

**Saturday, 27 September 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15/10:15</td>
<td><strong>PATIENT CASES</strong>&lt;br&gt;Immunotherapy or targeted therapy for oncogene&lt;br&gt;addicted melanoma&lt;br&gt;Co-Chairs: Anna Maria Di Giacomo, Siena, Italy and James Larkin, London, UK&lt;br&gt;Choice of immunotherapy vs targeted therapy in first line (BRAF)&lt;br&gt;James Larkin, London, UK&lt;br&gt;Oncogene addicted brain metastases&lt;br&gt;Anna Maria Di Giacomo, Siena, Italy&lt;br&gt;Discussion</td>
</tr>
<tr>
<td>11:00/12:30</td>
<td><strong>EDUCATIONAL SESSION</strong>&lt;br&gt;Skin tumours update&lt;br&gt;Chair: Jürgen Becker, Graz, Austria&lt;br&gt;Co-Chair: to be announced&lt;br&gt;Merkel cell carcinoma&lt;br&gt;Jürgen Becker, Graz, Austria&lt;br&gt;Adjuvant treatment of melanoma&lt;br&gt;Olivier Michielin, Lausanne, Switzerland&lt;br&gt;Targeted therapy and immunotherapy for melanoma&lt;br&gt;David Solit, New York, NY, US</td>
</tr>
<tr>
<td>16:00/17:30</td>
<td><strong>SPECIAL SYMPOSIUM</strong>&lt;br&gt;The science behind combinations with immunotherapy in melanoma&lt;br&gt;Chair: John Haanen, Amsterdam, Netherlands&lt;br&gt;Co-Chair: Christian Blank, Amsterdam, Netherlands&lt;br&gt;Introduction&lt;br&gt;Christian Blank, Amsterdam, Netherlands&lt;br&gt;The tumour microenvironment as a barrier for immune destruction of cancer&lt;br&gt;Jürgen Becker, Graz, Austria&lt;br&gt;Rationale to combine immunotherapy with physical therapy&lt;br&gt;Kevin Harrington, London, UK&lt;br&gt;Which systemic therapies should be combined to immunotherapy?&lt;br&gt;Christian Blank, Amsterdam, Netherlands&lt;br&gt;Combining immunotherapies&lt;br&gt;Antoni Ribas, Los Angeles, CA, US&lt;br&gt;Conclusions and clinical perspectives&lt;br&gt;John Haanen, Amsterdam, Netherlands</td>
</tr>
</tbody>
</table>

### SCIENTIFIC COMMITTEE

Caroline Robert, Villejuif, France, Chair

- Paolo Ascierto, Naples, Italy
- Jürgen Becker, Graz, Austria
- Christian Blank, Amsterdam, Netherlands
- Reinhard Dummer, Zurich, Switzerland
- Jean-Jacques Grob, Marseille, France
- José Antonio López Martín, Madrid, Spain
- Richard Marais, Manchester, UK
- Grant McArthur, Melbourne, Australia
- Olivier Michielin, Lausanne, Switzerland
- Mark Middleton, Oxford, UK
- Antoni Ribas, Los Angeles, CA, US
Sunday, 28 September 2014

10:30/11:30 PATIENT CASES
How does one manage rare neuroendocrine malignancies?
Co-Chairs: Piero Ferolla, Perugia, Italy and Alexandria Phan, Houston, TX, US
Malignant bronchial carcinoid tumour
Piero Ferolla, Perugia, Italy
Paragangioma
Alexandria Phan, Houston, TX, US
Discussion

16:00/17:30 SPECIAL SYMPOSIUM
Neuroendocrine tumours: The cutting edge and a glimpse into the future
Chair: Ian Chau, Sutton, UK
Co-Chair: Philippe Ruszniewski, Clichy, France
Introduction
Philippe Ruszniewski, Clichy, France
Towards new molecular classification for neuroendocrine tumours
Aldo Scarpa, Verona, Italy
Tools to evaluate tumour response to therapy: Imaging
Marie-Pierre Vullièreme, Clichy, France
Tools to evaluate tumour response to therapy: Tissue biomarkers
Tim Meyer, London, UK
Do minimal access and robotic surgery bring benefit to neuroendocrine tumours?
Massimo Falconi, Ancona, Italy
Current landscape and ongoing clinical trials for medical therapy in neuroendocrine tumours
Marianne Pavel, Berlin, Germany
Clinical trial endpoints relevant to patients/society for rare tumours and conclusions
Ian Chau, Sutton, UK

Monday, 29 September 2014

11:00/12:30 EDUCATIONAL SESSION
Update on all neuroendocrine tumours
Chair: Ian Chau, Sutton, UK
Co-Chair: Alfredo Carrato, Madrid, Spain
Classification and tumour biology
Kjell Öberg, Uppsala, Sweden
Molecular imaging and peptide receptor radionuclide therapy (PRRT)
Lisa Bodei, Milan, Italy
Classical and targeted therapies in GEP-NETs
Ian Chau, Sutton, UK

SCIENTIFIC COMMITTEE
Ian Chau, Sutton, UK, Chair
Massimo Falconi, Ancona, Italy
Ashley Grossman, Headington, UK
Dik Kwekkeboom, Rotterdam, Netherlands
Steven Libutti, New York, NY, US
Kjell Öberg, Uppsala, Sweden
Marianne Pavel, Berlin, Germany
Alexandria Phan, Houston, TX, US
Guido Rindi, Rome, Italy
Philippe Ruszniewski, Clichy, France
Britt Skogseid, Uppsala, Sweden
Saturday, 27 September 2014

16:00 - 17:00

PATIENT CASES

Avoiding overdiagnosis and overtreatment in cancer screening: Assessing the role of personalised screening
Co-Chairs: Harry de Koning, Rotterdam, Netherlands; Silvia de Sanjose, L’Hospitalet de Llobregat, Spain and Nereo Segnan, Turin, Italy

Precision medicine in cancer prevention: From genomic to stratified, population based cancer screening
Nereo Segnan, Turin, Italy

Personalised versus organised approaches to screening of cervical cancer: Can we fit both?
Silvia de Sanjose, L’Hospitalet de Llobregat, Spain

Pulmonary nodules and CT-lung cancer screening
Harry de Koning, Rotterdam, Netherlands

Discussion

Monday, 29 September 2014

14:15 - 15:45

SPECIAL SYMPOSIUM

The impact on health services from personalised targeted therapies
Chair: Josep M. Borras, Barcelona, Spain
Co-Chair: Tit Albreht, Ljubljana, Slovenia

Introduction
Tit Albreht, Ljubljana, Slovenia

Confronting health services: Targeting the baby boom
Valery Lemmens, Eindhoven, Netherlands

Budget impact vs cost effectiveness: Implications for personalised cancer therapies
Yolande Lievens, Ghent, Belgium

Evolution of pricing and reimbursement structure of cancer therapies in Europe
Richard Sullivan, London, UK

Personalised medicine in National Cancer Plans: How can innovation be translated into policy?
Jose Maria Martin Moreno, Valencia, Spain

Conclusions and clinical perspectives
Josep M. Borras, Barcelona, Spain

SCIENTIFIC COMMITTEE

Josep Maria Borras, Barcelona, Spain, Chair

Tit Albreht, Ljubljana, Slovenia
Freddie Bray, Lyon, France
Jack Cuzick, London, UK
Harry de Koning, Rotterdam, Netherlands
Silvia de Sanjose, L’Hospitalet de Llobregat, Spain
Silvano Gallus, Milan, Italy
Valery Lemmens, Eindhoven, Netherlands
Yolande Lievens, Ghent, Belgium
Jose M. Martin-Moreno, Valencia, Spain
Nereo Segnan, Turin, Italy

Session timings may be subject to change within the same day
Saturday, 27 September 2014

09:00/10:30  EDUCATIONAL SESSION
Biology must guide the treatment in sarcoma
Chair: Silvia Stacchiotti, Milan, Italy
Co-Chair: Jean-Yves Blay, Lyon, France
Sarcoma pathology for clinicians
A. Paolo dei Tos, Treviso, Italy
Could medical treatment be histology guided?
Silvia Stacchiotti, Milan, Italy
Gastrointestinal stromal tumours (GIST)
Sebastian Bauer, Essen, Germany

Sunday, 28 September 2014

16:00/17:00  PATIENT CASES
The management of isolated lung metastases from soft tissue sarcomas (STS)
Co-Chairs: Axel Le Cesne, Villejuif, France; Aisha Miah, London, UK and Ugo Pastorino, Milan, Italy
Surgery: Why and when?
Ugo Pastorino, Milan, Italy
Systemic treatment for a patient with isolated lung metastases: What is the current standard?
Axel Le Cesne, Villejuif, France
The sense and non-sense of radiotherapy and radiofrequency ablation to control isolated lung metastases
Aisha Miah, London, UK
Discussion

Monday, 29 September 2014

11:00/12:30  SPECIAL SYMPOSIUM
Controversies in the neo-adjuvant treatment of localised soft tissue sarcomas (STS)
Chair: Alessandro Gronchi, Milan, Italy
Co-Chair: Stefan Sleijfer, Rotterdam, Netherlands
Introduction: Induction therapy in localised STS: For whom and with what?
Stefan Sleijfer, Rotterdam, Netherlands
Evolving biology of sarcoma
Jean-Yves Blay, Lyon, France
Is there a role for neo-adjuvant systemic treatment in STS?
Javier Martin Broto, Palma de Mallorca, Spain
InnovATIVE combination of targeted agents with radiotherapy
Rick Haas, Amsterdam, Netherlands
Local treatment after neo-adjuvant therapy
Piotr Rutkowski, Warsaw, Poland
Conclusions and clinical perspectives
Alessandro Gronchi, Milan, Italy

SCIENTIFIC COMMITTEE
Stefan Sleijfer, Rotterdam, Netherlands, Chair
Thomas Brodowicz, Vienna, Austria
Robin Jones, Seattle, WA, US
Bernd Kasper, Mannheim, Germany
Axel Le Cesne, Villejuif, France
Cecile Le Pechoux, Villejuif, France
Javier Martin Broto, Palma de Mallorca, Spain
Aisha Miah, London, UK
Nicolas Penel, Lille, France
Piotr Rutkowski, Warsaw, Poland
Winette van der Graaf, Nijmegen, Netherlands
Kees Verhoef, Rotterdam, Netherlands
**SUPPORTIVE AND PALLIATIVE CARE**

**Saturday, 27 September 2014**

**09:15/10:45**
**EDUCATIONAL SESSION**
- **Symptoms in oncology**
  Chair: Carla Ripamonti, Milan, Italy
  Co-Chair: Florian Strasser, St. Gallen, Switzerland
  Organ toxicities from targeted therapies
  Carla Ripamonti, Milan, Italy
  Metabolic disorders
  Viktor Grünwald, Hannover, Germany
  Complications arising with compliances
  Andrea Antonuzzo, Pisa, Italy

**11:45/12:45**
**PATIENT CASES**
- **Pregnancy and fertility preservation in patients with cancer**
  Co-Chairs: Hatem A. Azim, Brussels, Belgium and Hamish Wallace, Edinburgh, UK
  How to manage a pregnant woman with cancer
  Hatem A. Azim, Brussels, Belgium
  Fertility preservation in the cancer patient
  Hamish Wallace, Edinburgh, UK
  Discussion

**15:55/17:30**
**SPECIAL SYMPOSIUM**
- **Targeting precision medicine toxicity**
  Chair: Mario Dicato, Luxembourg
  Co-Chair: Fausto Roila, Terni, Italy
  Introduction
  Mario Dicato, Luxembourg
  Cardiac toxicity
  Lillian Siu, Toronto, ON, Canada
  Pulmonary toxicity
  Guy Meyer, Paris, France
  Skin toxicity
  Caroline Robert, Villejuif, France
  Endocrine toxicity
  Fausto Roila, Terni, Italy
  Osteoarticular toxicity
  Ignacio Tusquets, Barcelona, Spain
  GI toxicity
  Jervoise Andreyev, London, UK

**Monday, 29 September 2014**

**08:00/09:00**
**CHALLENGE YOUR EXPERT (CYE)**
- Thromboembolic disorders in oncology: Present status and novel agents
  Speaker: Mario Dicato, Luxembourg

**Tuesday, 30 September 2014**

**08:00/09:00**
**CYE (REPETITION)**
- Thromboembolic disorders in oncology: Present status and novel agents
  Speaker: Mario Dicato, Luxembourg

---

**SCIENTIFIC COMMITTEE**

**Mario Dicato, Luxembourg, Chair**
- Raphael Catane, Tel Hashomer, Israel
- Petra Feyer, Berlin, Germany
- Pere Gascon, Barcelona, Spain
- Joarn Herrassted, Odense, Denmark
- Ivan Krakowski, Vandoeuvre-les-Nancy, France
- Alex Molasiotis, Hong Kong, China
- Carla Ripamonti, Milan, Italy
- César Rodriguez, Salamanca, Spain
- Fausto Rolia, Terni, Italy
- Florian Scotté, Paris, France
- Simon Van Belle, Ghent, Belgium
Friday, 26 September 2014

12:00/13:15  ESMO 2014 Opening Session

ESMO Presidential Address
Rolf A. Stahel, Zurich, Switzerland
Presentation of the ESMO Award by
Josep Tabernero, Barcelona, Spain
ESMO Award lecture
To be announced
Presentation of the ESMO Hamilton Fairley Award by
Josep Tabernero, Barcelona, Spain
ESMO Hamilton Fairley Award lecture
To be announced
Presentation of the ESMO Lifetime Achievement Award by
Josep Tabernero, Barcelona, Spain
ESMO Lifetime Achievement Award lecture
To be announced
ESMO 2014 Scientific Address
Johann S. de Bono, Sutton, UK
Welcome reception

Saturday, 27 September 2014

08:00/09:00  CHALLENGE YOUR EXPERT (CYE)
Is hormone therapy really harmless in elderly people?
Speaker: Matti Aapro, Genolier, Switzerland

11:00/12:30  SPECIAL SESSION - ESMO COMMUNITY ONCOLOGY WORKING GROUP (COWG)
Optimal use of systemic therapy in the palliative setting
Chair: Robert Eckert, Wendlingen, Germany
Co-Chair: Michalis Karamouzis, Athens, Greece
The who and where of cancer care in Europe: Insights from a community oncology survey among ESMO National Representatives
Robert Eckert, Wendlingen, Germany
When to start systemic therapy: Indications for initiation of chemotherapy vs watchful waiting
Ian Tannock, Toronto, ON, Canada
Have a (systemic therapy) break: Optimal duration of systemic therapy in common tumours
Richard Hemmann, Basel, Switzerland
Trials and tribulations: Lifetime experiences of a medical oncologist on chemotherapy intensification
To be announced
It’s time to stop: When to initiate palliative/supportive therapy
Sofia Braga, Lisbon, Portugal
Conclusions
Michalis Karamouzis, Athens, Greece

14:15/15:45  JOINT SYMPOSIUM: ESMO EMERGING COUNTRIES COMMITTEE (ECC) - AORTIC-SLACOM-UICC-WHO
Personalised cancer care in countries with limited resources
Details to be announced

16:00/17:30  SPECIAL SESSION
Liquid biopsy: Monitoring tumour-derived cell-free DNA, circulating tumour cells (CTC) and exosomes in patients with solid tumours
Chair: Alberto Bardelli, Turin, Italy
Co-Chair: Carlos Caldas, Cambridge, UK
Introduction
Carlos Caldas, Cambridge, UK
Clinical applications for microRNAs in lung cancer
Carlo Croce, Columbus, OH, US
Circulating tumour cells: Isolation, enrichment and clinical value in breast cancer
Michail Ignatiadis, Brussels, Belgium
Liquid biopsies: Genotyping circulating tumour DNA in colorectal cancer
Alberto Bardelli, Turin, Italy
The potential of circulating tumour cells as a liquid biopsy to guide therapy in prostate cancer
Klaus Pantel, Hamburg, Germany
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Carlos Caldas, Cambridge, UK
Conclusions and clinical perspectives
Alberto Bardelli, Turin, Italy
Sunday, 28 September 2014

08:00/09:00  CYE (REPEITION)
Is hormone therapy really harmless in elderly people?
Speaker: Matti Aapro, Genolier, Switzerland

10:45/12:45  ESMO Clinical Practice Guidelines 1
Chair: Enriqueta Felip, Barcelona, Spain
Co-Chair: Nicholas Pavlidis, Ioannina, Greece
Introduction to the ESMO CP Guidelines
Enriqueta Felip, Barcelona, Spain
Questionnaire
Nicholas Pavlidis, Ioannina, Greece
Advanced NSCLC case presentation
Speaker: Stefan Zimmermann, Fribourg, Switzerland
Discussant: Solange Peters, Lausanne, Switzerland
Questions and answers
Gastric marginal zone lymphoma or MALT type case presentation
Speaker: To be announced
Discussant: Emanuele Zucca, Bellinzona, Switzerland
Questions and answers
High-grade glioma case presentation
Speaker: Katharina Seystahl, Zurich, Switzerland
Discussant: Roger Stupp, Zurich, Switzerland
Questions and answers
Head & neck cancer: HPV case presentation
Speaker: To be announced
Discussant: Lisa Licitra, Milan, Italy
Questions and answers

13:45/15:45  ESMO Clinical Practice Guidelines 2
Chair: Andrés Cervantes, Valencia, Spain
Co-Chair: George Pentheroudakis, Ioannina, Greece
Introduction to the ESMO CP Guidelines
Andrés Cervantes, Valencia, Spain
Questionnaire
George Pentheroudakis, Ioannina, Greece
Advanced melanoma case presentation
Speaker: Simone Goldinger, Zurich, Switzerland
Discussant: Reinhard Dummer, Zurich, Switzerland
Questions and answers
Gestational trophoblastic disease case presentation
Speaker: Finke Froeling, London, UK
Discussant: Michael Seckl, London, UK
Questions and answers
Waldenström's macroglobulinaemia case presentation
Speaker: To be announced
Discussant: Christian Buske, Ulm, Germany
Questions and answers
Cervical cancer case presentation
Speaker: To be announced
Discussant: Cristiana Sessa, Bellinzona, Switzerland
Questions and answers

16:00/17:30  SPECIAL SESSION - ESMO EMERGING COUNTRIES AND PUBLIC POLICY COMMITTEES
Availability of anti-neoplastic medicines in Europe
Details to be announced

16:00/17:30  JOINT SYMPOSIUM: ESMO - EONS
Oral tumour therapy: Collaboration and coordination of healthcare professional activities to enhance patient adherence
Co-Chairs: Andrés Cervantes, Valencia, Spain and Anita Margulies, Zurich, Switzerland
Issues and challenges in oral tumour therapy adherence
Anita Margulies, Zurich, Switzerland
Clinical issues in patients receiving oral tumour therapy: How can we improve adherence?
Alfredo Carano, Madrid, Spain
Nurse led clinics: Involvement in patient management and follow up
To be announced
Oral tumour therapy in Emerging Countries: Special problems encountered
Alexandru Eniu, Cluj Napoca, Romania
Options and strategies: Project in action: Oral tumour therapy-adherence and safety
Anita Margulies, Zurich, Switzerland
Conclusions
Andrés Cervantes, Valencia, Spain
Monday, 29 September 2014

08:00/09:00
CHALLENGE YOUR EXPERT (CYE)
Current diagnosis and treatment of CUP
Speaker: George Pentheroudakis, Ioannina, Greece

09:15/10:45
SPECIAL SESSION
Precision medicine: Panacea or false dawn?
Chair: Johann S. de Bono, Sutton, UK
Co-Chair: José Baselga, New York, NY, US
Introduction
Johann S. de Bono, Sutton, UK
Visualising the true spectrum of cancer: Will we get convergence from divergence?
Peter Campbell, Cambridge, UK
Drug registration strategies: How will these change with precision medicine?
José Baselga, New York, NY, US
Intrapatent heterogeneity and clonal evolution: What precision medicine?
Charles Swanton, London, UK
Precision medicine: Panacea or false dawn?
Andrew Hughes, Macclesfield, UK
Conclusions
Johann S. de Bono, Sutton, UK

11:00/12:30
JOINT SYMPOSIUM: ESMO - ASCO
The evolution of the clinical trials landscape
Co-Chairs: Rolf A. Stahel, Zurich, Switzerland and Peter Yu, Sunnyvale, CA, US
Introduction
Peter Yu, Sunnyvale, CA, US
Novel molecular studies to inform the conduct of oncology clinical trials: from battle to master protocols
Roy Herbst, New Haven, CT, US
Adapting organisation and research infrastructures at Gustave Roussy for today’s clinical research programmes
Alexander M.M. Eggermont, Villejuif, France
Can Collaborative Molecular Screening Platforms (CMSPs) support new forms of cancer clinical research? The example of the EORTC SPECTA programme
Denis Lacombe, Brussels, Belgium
The evolution of clinical trials: Randomised controlled trials to real world studies
Gary Lyman, Seattle, WA, US
Conclusions
Rolf A. Stahel, Zurich, Switzerland

14:15/15:45
JOINT SYMPOSIUM: ESMO - SEOM
Investigation driven precision oncology
Co-Chairs: Rolf A. Stahel, Zurich, Switzerland and Pilar Garrido, Madrid, Spain
Introduction
Pilar Garrido, Madrid, Spain
Translating breast cancer genomics into clinic
Miguel Martin, Madrid, Spain
Can we do better with our current therapies for NSCLC?
The Spanish Lung Cancer Group approach
Rafael Rosell, Badalona, Spain
TTD contribution to precision oncology
Enrique Aranda, Cordoba, Spain
The European perspective of academic research: The way to move forwards
To be announced
Conclusions
To be announced

16:00/17:30
EDUCATIONAL SESSION
Cancer in young adults (18-35)
Chair: Sophie Fosså, Oslo, Norway
Co-Chair: George Pentheroudakis, Ioannina, Greece
Epidemiology, risk factors, genetics and molecular biology
Sophie Fosså, Oslo, Norway
Managing the most common tumours affecting young adults: Peculiarities, controversies and clinical research
Valérie Laurence, Paris, France
Follow up and long term toxicity of young adult cancer survivors
Daniel Stark, Leeds, UK

Tuesday, 30 September 2014

08:00/09:00
CYE (REPETITION)
Current diagnosis and treatment of CUP
Speaker: George Pentheroudakis, Ioannina, Greece

09:00/13:00
CONGRESS HIGHLIGHTS
The best of the ESMO 2014 Congress

Controversy sessions will be included in the programme and details will be made available at the same time as the abstract-related sessions.
### Friday, 26 September 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>YO MASTERCLASS</strong></td>
<td><strong>ESMO YOs meet the EACR: Integrating basic science into clinical research</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Raffaele Califano, Manchester, UK</td>
<td>Co-Chair: Leticia De Mattos-Arruda, Barcelona, Spain</td>
</tr>
<tr>
<td>17:00</td>
<td><strong>ESMO YOs meet the EACR: Integrating basic science into clinical research</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Raffaele Califano, Manchester, UK</td>
<td>Co-Chair: Leticia De Mattos-Arruda, Barcelona, Spain</td>
</tr>
<tr>
<td></td>
<td>Speaker: Joan Seoane, Barcelona, Spain</td>
<td>Session Shooter: Matthias Preusser, Vienna, Austria</td>
</tr>
<tr>
<td></td>
<td>Speaker: Carlos Caldas, Cambridge, UK</td>
<td>Session Shooter: Sophie Postel-Vinay, London, UK</td>
</tr>
<tr>
<td></td>
<td>Speaker: Klaus Pantel, Hamburg, Germany</td>
<td>Next generation of clinical trial design</td>
</tr>
<tr>
<td></td>
<td>Speaker: Joan Seoane, Barcelona, Spain</td>
<td>Session Shooter: Matthias Preusser, Vienna, Austria</td>
</tr>
<tr>
<td></td>
<td>Speaker: Carlos Caldas, Cambridge, UK</td>
<td>Session Shooter: Sophie Postel-Vinay, London, UK</td>
</tr>
<tr>
<td></td>
<td>Speaker: Klaus Pantel, Hamburg, Germany</td>
<td>Next generation of clinical trial design</td>
</tr>
<tr>
<td></td>
<td>Speaker: Joan Seoane, Barcelona, Spain</td>
<td>Session Shooter: Matthias Preusser, Vienna, Austria</td>
</tr>
<tr>
<td></td>
<td>Speaker: Carlos Caldas, Cambridge, UK</td>
<td>Session Shooter: Sophie Postel-Vinay, London, UK</td>
</tr>
<tr>
<td>17:15</td>
<td><strong>VESALIUS TALK</strong></td>
<td><strong>Paving your own path to success</strong></td>
</tr>
<tr>
<td>17:45</td>
<td><strong>VESALIUS TALK</strong></td>
<td><strong>Paving your own path to success</strong></td>
</tr>
<tr>
<td></td>
<td>Mentors: Christoph Zielinski, Vienna, Austria</td>
<td>Angelo Di Leo, Prato, Italy and Nicholas Pavlidis, Ioannina, Greece</td>
</tr>
</tbody>
</table>

### Saturday, 27 September 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td><strong>YO BREAKFAST</strong></td>
<td><strong>How to address the media: Practical advice for young oncologists</strong></td>
</tr>
<tr>
<td>08:45</td>
<td><strong>YO BREAKFAST</strong></td>
<td><strong>How to address the media: Practical advice for young oncologists</strong></td>
</tr>
<tr>
<td></td>
<td>Session Coordinators: Margaret Hutka, London, UK and Matthias Preusser, Vienna, Austria</td>
<td>Speaker: Jilly Carter, Wallingford, UK</td>
</tr>
</tbody>
</table>

### Sunday, 28 September 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td><strong>YO BREAKFAST</strong></td>
<td><strong>How to find the right work-life balance: Time management for young oncologists</strong></td>
</tr>
<tr>
<td>08:45</td>
<td><strong>YO BREAKFAST</strong></td>
<td><strong>How to find the right work-life balance: Time management for young oncologists</strong></td>
</tr>
<tr>
<td></td>
<td>Session Coordinators: Giannis Mountzios, Athens, Greece and Susana Banerjee, London, UK</td>
<td>Speaker: Pia Osterlund, Helsinki, Finland</td>
</tr>
</tbody>
</table>

### Monday, 29 September 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td><strong>YO BREAKFAST</strong></td>
<td><strong>Risks and boundaries: The doctor / cancer patient relationship</strong></td>
</tr>
<tr>
<td>08:45</td>
<td><strong>YO BREAKFAST</strong></td>
<td><strong>Risks and boundaries: The doctor / cancer patient relationship</strong></td>
</tr>
<tr>
<td></td>
<td>Session Coordinators: Mila Petrova, Sofia, Bulgaria and Valentina Guanieri, Padua, Italy</td>
<td>Speaker: Lesley Fallowfield, Brighton, UK</td>
</tr>
<tr>
<td>09:00</td>
<td><strong>YO SPECIAL SESSION</strong></td>
<td><strong>Fellowships in Europe: Educational opportunities for young oncologists</strong></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>YO SPECIAL SESSION</strong></td>
<td><strong>Fellowships in Europe: Educational opportunities for young oncologists</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Giampaolo Tortora, Verona, Italy</td>
<td>Co-Chair: Raffaele Califano, Manchester, UK</td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>The ESMO Fellowship Programme</td>
</tr>
<tr>
<td></td>
<td>Practical tips from a former fellow</td>
<td>The ESMO Fellowship Programme</td>
</tr>
<tr>
<td></td>
<td>Best fellowship project 1</td>
<td>The ESMO Fellowship Programme</td>
</tr>
<tr>
<td></td>
<td>Best fellowship project 2</td>
<td>The ESMO Fellowship Programme</td>
</tr>
<tr>
<td></td>
<td>Awards: Presentation of the ESMO 2014 fellows and the 2013 best exam</td>
<td>Awards: Presentation of the ESMO 2014 fellows and the 2013 best exam</td>
</tr>
</tbody>
</table>

**YOUNG ONCOLOGISTS COMMITTEE**

- Raffaele Califano, Manchester, UK, Chair
- Susana Banerjee, London, UK
- Jesus Corral, Seville, Spain
- Evandro De Azambuja, Brussels, Belgium
- Leticia De Mattos-Arruda, Barcelona, Spain
- Valentina Guanieri, Padua, Italy
- Margaret Hulka, London, UK
- Karin Jordan, Halle, Germany
- Erika Martinelli, Naples, Italy
- Giannis Mountzios, Athens, Greece
- Mila Petrova, Sofia, Bulgaria
- Sophie Postel-Vinay, London, UK
- Matthias Preusser, Vienna, Austria
- Camilla Qvortrup, Odense, Denmark
- Nikita Volkov, St. Petersburg, Russian Federation
THE ONLINE ACCESS TO ESMO’S SCIENTIFIC AND EDUCATIONAL CONTENT.

Your one-stop shop for exclusive medical oncology content, from news and conference presentations to guidelines, handbooks and treatment factsheets. All available at your desk, or on the go.

MEDICAL ONCOLOGY IS A FAST-EVOLVING FIELD, ONCOLOGYPRO WILL HELP YOU KEEP UP-TO-DATE.

oncologypro.esmo.org
### Saturday, 27 September 2014

**10:00/13:00**  
**Cancer research**  
Clinical trials: Making statistics a little bit easier to understand!  
Clinical trials – Endpoints  
Patient involvement in cancer clinical research  
Introduction: Generating patient data, tissue and experiences…

**14:00/15:30**  
**Treatment & living (part 1)**  
ESMO Patient Cancer Guides  
Cancer & nutrition

**16:00/17:45**  
**Treatment & living (part 2)**  
Patient interaction with multidisciplinary teams (MDTs)  
Highlighting some social challenges

**17:45**  
**End of the 1st day – Get together / Networking**

### Sunday, 28 September 2014

**10:00/13:00**  
**Capacity building**  
The ESMO “Patient Advocacy Best Practice Award” 2014  
Why strategic planning is important and valuable for patient groups?

**14:00/15:30**  
**Patient advocacy (Part 1)**  
An interesting journey through European healthcare politics  
RARE CANCERS in EUROPE: More common than you think!

**16:00/17:30**  
**Patient advocacy (Part 2)**  
European cross border healthcare directive

**17:30**  
**End of the 2nd day – Farewell**

---

**ESMO PATIENT ADVOCACY TRACK TASK FORCE**  
Lorenz Jost, Kantonsspital and Chair of the ESMO CPWG Switzerland

- Raphael Catane  
- Shiba Medical Centre, Israel  
- Philip Davies  
- European Cervical Cancer Association, UK  
- Francesco De Lorenzo  
- European Cancer Patient Coalition, Italy  
- Louis Denis  
- Europa Uomo, Belgium  
- Jan Geissler  
- CML Advocates Network, Germany  
- Gabriela Kornek  
- Medical University of Vienna, Austria  
- Stella Kyriakides  
- Europa Donna Cyprus, Cyprus

- Anita Margulies  
- European Oncology Nursing Society, Switzerland  
- Kathy Oliver  
- International Brain Tumours Alliance, UK  
- Zorana Stokic  
- Europacolon, Serbia  
- Wendy Tse Yared  
- Association of European Cancer Leagues, Belgium  
- Stefania Vallone  
- Global Lung Cancer Coalition, Italy  
- Anita Waidmann  
- Myeloma Euronet, Germany  
- Markus Wartenberg  
- Sarcoma Patients EuroNet, IKCC, Germany

---

Final details of the programme will be published online at esmocongress.org